Physiologically-based pharmacokinetic models for children: Starting to reach maturation?

Physiologically-based pharmacokinetic models for children: Starting to reach maturation?

Publication: Pharmacol Ther
Software: GastroPlus®

Developmental changes in children can affect the disposition and clinical effects of a drug, indicating that scaling an...

Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer

Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer

Publication: Acta Pharmacol Sin
Software: ADMET Predictor®

Alflutinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations.

(Q)SAR tools for the prediction of mutagenic properties: Are they ready for application in pesticide regulation?

(Q)SAR tools for the prediction of mutagenic properties: Are they ready for application in pesticide regulation?

Publication: Pest Manag Sci
Software: ADMET Predictor®

The assessment of human health risks resulting from the presence of metabolites in groundwater and food residues has become an important element...

Generalized PBPK Model for Evaluation of Inhalation Exposure of Volatile Organic Compounds

Generalized PBPK Model for Evaluation of Inhalation Exposure of Volatile Organic Compounds

Conference: SOT
Software: GastroPlus®
Division: PBPK

Physiologically based pharmacokinetic modeling (PBPK) is a valuable tool to evaluate inhalation exposure of volatile organic compounds (VOCs).

Synergy Between Two Mechanisms of Action Contributes to Species Differences in the Liver Safety Profile for PF-04895162

Synergy Between Two Mechanisms of Action Contributes to Species Differences in the Liver Safety Profile for PF-04895162

Conference: SOT
Software: DILIsym®

PF-04895162 (ICA-105665), a drug in development for the treatment of epilepsy, was terminated after transaminase elevations (up to grade...